Aclarion (ACON) PE Ratio: History & Chart

Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/E ratio is N/A as of 2026-10-06T21:30:35.745Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:30:35.745Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote price: 2.29
Unrounded diluted TTM EPS · period ending 2026-06-30: -7.6

FMP input reference: 1aa4897ea94b4447735fa2b7e4a8bb5a18d1bcefabda34b81af7232f4abbcb6a

Forward PE Ratio|PEG Ratio|P/B Ratio|EPS|All Metrics

ACON PE Ratio Metrics

PE RATIO

N/A

ACON Competitors' PE Ratio

ACON

Aclarion, Inc.

Current

Market Cap

$6.60M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ENSC

Ensysce Biosciences, Inc.

vs ACON

Market Cap

$6.60M

PE Ratio

N/A

TTM Avg

4788.36

3Y Avg

147312.95

5Y Avg

148989.26

BMRA

Biomerica, Inc.

vs ACON

Market Cap

$6.61M

PE Ratio

N/A

TTM Avg

278.25

3Y Avg

163.06

5Y Avg

336.05

ENVB

Enveric Biosciences, Inc.

vs ACON

Market Cap

$6.58M

PE Ratio

N/A

TTM Avg

47.75

3Y Avg

83.50

5Y Avg

106.23

BOLT

Bolt Biotherapeutics, Inc.

vs ACON

Market Cap

$6.74M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

XCUR

Exicure, Inc.

vs ACON

Market Cap

$6.88M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FEMY

Femasys Inc.

vs ACON

Market Cap

$6.28M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KALA

KALA BIO, Inc.

vs ACON

Market Cap

$7.04M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CURX

Curanex Pharmaceuticals Inc Common Stock

vs ACON

Market Cap

$7.07M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SCNX

Scienture Holdings, Inc.

vs ACON

Market Cap

$6.11M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Aclarion, Inc. (ACON)	$6.60M	N/A	N/A	N/A	N/A
Ensysce Biosciences, Inc. (ENSC)vs ›	$6.60M	N/A	4788.36	147312.95	148989.26
Biomerica, Inc. (BMRA)vs ›	$6.61M	N/A	278.25	163.06	336.05
Enveric Biosciences, Inc. (ENVB)vs ›	$6.58M	N/A	47.75	83.50	106.23
Bolt Biotherapeutics, Inc. (BOLT)vs ›	$6.74M	N/A	N/A	N/A	N/A
Exicure, Inc. (XCUR)vs ›	$6.88M	N/A	N/A	N/A	N/A
Femasys Inc. (FEMY)vs ›	$6.28M	N/A	N/A	N/A	N/A
KALA BIO, Inc. (KALA)vs ›	$7.04M	N/A	N/A	N/A	N/A
Curanex Pharmaceuticals Inc Common Stock (CURX)vs ›	$7.07M	N/A	N/A	N/A	N/A
Scienture Holdings, Inc. (SCNX)vs ›	$6.11M	N/A	N/A	N/A	N/A

P/E Comparison

Trailing P/E

N/A

Forward P/E

N/A

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$2.29

÷

Forward EPS (Est.)

$-4.51

=

Forward P/E

N/A

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

See the Lowest P/E Ratio Stocks ranking →

PE Ratio: N/A

ACON PE Ratio Metrics

ACON Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics